~~<i id='12A18DEEE7'><strike id='12A18DEEE7'><tt id='12A18DEEE7'><pre id='12A18DEEE7'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

hotspot

author：entertainment 2025-08-11 02:12:28 - browse：32141

The Food and Drug Administration on Thursday approved a gene therapy to treat people with hemophilia A, an inherited and rare bleeding disorder.

The treatment, called Roctavian, is made by BioMarin Pharmaceutical. It was first approved in Europe in August 2022.

Roctavian is a one-time therapy that, in clinical trials, dramatically reduced bleeding episodes and helped patients live without the blood transfusions used to treat the disease. The FDA first rejected Roctavian in 2020, asking BioMarin to amass more data on its safety and long-term durability, and then delayed its decision again to account for additional evidence.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The high cost of giving birth even with insurance
Next article： Readout Newsletter: Ironwood, Pfizer, FogPharma updates

entertainment

hotspot

entertainment

focus

entertainment

hotspot

DavidLRyan/TheBostonGlobeWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourb

WSS

U.S. death rates show how politics are affecting public health

ALS groups 'won't be played again' by the FDA, drug sponsors

Why getting cancer drugs just got harder for rural patients

Duchenne drug from Nippon Shinyaku fails in rare confirmatory trial

Medical students need to learn the potent medicine of empathy

Beyond aggravation: Constipation is an American epidemic

knowledge

hotspot

entertainment

Hollywood unions extend contract negotiations for actors

New research sheds light on how often breast cancer is overdiagnosed

As demand for Covid shots wanes, Moderna seeks its next success

House looks to weaken Medicare negotiation

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Why some fertility treatments produce more boy babies

Malaria cases in Florida and Texas: Here’s what you need to know

Clinical trials giant ICON acquires HumanFirst

State Dept. review finds Biden bears some blame for Afghanistan failures

Change Healthcare cyberattack outage could last weeks

hotspot

FDA does about

Why getting cancer drugs just got harder for rural patients

U.S. death rates show how politics are affecting public health

Clinical trials giant ICON acquires HumanFirst

Why getting cancer drugs just got harder for rural patients

Clinical trials giant ICON acquires HumanFirst

entertainment

focus

entertainment

hotspot